AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Measurement Of Antibody-Secreting Cells Can Predict Effectiveness Of E. coli Vaccine.(Brief Article)
2001 MAY 16 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Circulating immunoglobulin A (IgA) antibody-secreting cells (ASCs) can be a good indication of how well a vaccine against Escherichia coli will work, say microbiologists.
M. Jertborn and colleagues at Gothenburg University, Sweden, studied the immunogenicity of different preparations of an oral inactivated enterotoxigenic E. coli (ETEC) vaccine consisting of recombinant cholera toxin B (CTB) subunit and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs).
The majority of Swedish volunteers, who had not been previously exposed to E. coli infection, produced significant IgA responses against CTB and the various CFA components, regardless of the vaccine preparation given, reported Jertborn and coworkers.
"The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after each dose of ETEC vaccine," they noted.
When one-third dose of E. coli bacteria was given, subjects showed lower frequencies of IgA ASC responses against all the different CFAs compared with two, full vaccine doses ("Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral ...
- Nebraska Research Studies Confirm Efficacy of E. coli Vaccine; - Significant...
- Press release article from: PR Newswire October 21, 2003 700+ words
...efficacious and commercially viable E. coli vaccine," said Graeme McRae, President and...profile of the original prototype E. coli vaccine developed by Dr. Brett Finlay at the...Life Sciences have helped fund the E. coli vaccine research studies at the University of...
- ID Biomedical/Ribi ImmunoChem Begin Formulation Studies For Unique Intranasal...
- Press release article from: PR Newswire February 11, 1999 700+ words
...coli. ID Biomedical's prototypic E. coli vaccine is the subject of ongoing bacterial...University of British Columbia. The E. coli vaccine to be formulated by ID Vaccine and Ribi...of British Columbia are testing E. coli vaccine candidates in animal models. One form...
- Nebraska Research studies confirm efficacy of E coli vaccine - significant...
- News wire article from: Asia Africa Intelligence Wire October 21, 2003 700+ words
...mimicked the protein profile of the original prototype E coli vaccine developed by Dr Brett Finlay at the University of British...Canada programme to advance development of an effective E coli vaccine for cattle. Bioniche Life Sciences Inc is a leading Canadian...
- E. coli vaccine.(Poulvac E. coli attenuated vaccine)(Brief article)
- Magazine article from: Feedstuffs May 22, 2006 700+ words
E. coli vaccine: Fort Dodge Animal Health announced U.S. Department of Agriculture approval of Poulvac E. coli, a live attenuated vaccine...
- Recombinant E. coli vaccine promotes MHC class I-dependent antigen presentation.
- Newspaper article from: Gene Therapy Weekly January 9, 2003 700+ words
...efficient strategy for tumor immunotherapy." Radford and coauthors published their study in Gene Therapy (A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: Application to cancer immunotherapy. Gene Ther, 2002;9(21...
- Recombinant E. coli vaccine promotes MHC class I-dependent antigen...
- Newspaper article from: Cancer Weekly January 7, 2003 700+ words
...efficient strategy for tumor immunotherapy." Radford and coauthors published their study in Gene Therapy (A recombinant E. coli vaccine to promote MHC class I-dependent antigen presentation: Application to cancer immunotherapy. Gene Ther, 2002;9(21...
- IAH and VB TO COMMERCIALISE E-COLI VACCINE FOR POULTRY (will also commercialise...
- News wire article from: Asia Africa Intelligence Wire June 16, 2005 700+ words
...developed it by using two crucial strains, 078 and 02, out of the 14 strains of the disease. IAH and VB will also commercialise the first bio-film based E-Coli vaccine for sheep and cattle after its six-month trial that ends in Dec 2005.
- E. coli vaccine under review in U.S. and Canada.(Research)(Brief Article)
- Newspaper article from: Food Chemical News Binkley, Alex February 23, 2004 700+ words
A vaccine developed by Canadian researchers to reduce the level of E. coli 0157:H7 in cattle is under review by officials at USDA and the Canadian Food Inspection Agency. Scientists from the University of British Columbia and the University of Saskatchewan had worked on the vaccine for several
- E. coli vaccine for cattle being developed in Canada.(by Bioniche Life...
- Newspaper article from: Food Chemical News Binkley, Alex August 6, 2001 700+ words
Agriculture and Agri-Food Canada has loaned an Ontario biopharmaceutical company C$7.6 million to support the development of a vaccine to eradicate E. coli O157:H7 in cattle. Bioniche Life Sciences says the loan through the Technology Partnerships Canada program will speed the development and
- CFIA authorizes E. coli vaccine.(News Watch)
- Magazine article from: Feedstuffs January 1, 2007 700+ words
Bioniche Life Sciences Inc., a Canadian biopharmaceutical company, has received authorization from the Canadian Food Inspection Agency (CFIA) to distribute its Escherichia coli O157: H7 cattle vaccine to Canadian veterinarians under a Permit to Release Veterinary Biologics as specified in the
Source: HighBeam Research, Measurement Of Antibody-Secreting Cells Can Predict Effectiveness Of...